Nav: Home

VHIO scientists reveal novel drug-target to strangle sleeping cancer cells

June 26, 2018

  • Latest discovery promises new weaponry against dormant tumor cells to counteract resistance and prevent disease relapse.
  • Findings show epigenetic enzyme TET2 as an orchestrator of the control and survival of these cells as promoters of cancer recurrence.
  • TET2 inhibition proposed as an effective approach to prevent their seeding of metastasis.
  • Novel biomarker identified for DTC detection and to more precisely predict those patients at risk of recurrence.


Research spearhead by first author Isabel Puig, Post-Doctoral Fellow of the Vall d´Hebron Institute of Oncology's (VHIO) Stem Cells & Cancer Group, directed by Principal Investigator Héctor G. Palmer, has culminated in the discovery of a biomarker to identify dormant tumor cells (DTC), also known as slow-cycling cancer cells (SCCC), that, in their sleepy and silent state, go undetected by current treatments that have mostly been designed to target rapidly dividing tumor cells.

Having travelled undetected and settled in other parts of the body, when these DTC awake - the alarm clock trigger yet unknown - they behave like cancer stem cells, regenerate the original tumor and drive metastatic cell spread in patients thought to be cured.

Findings reported ahead of print today in the Journal of Clinical Investigation, reveal that a novel drug-target, the TET2 epigenetic enzyme, shows promise as a strategy to eliminate these sleeper yet murderous cells. Additionally, authors show that 5-Hydroxymethylcytosine (5hmC), generated by TET2, can be utilized as a biomarker for chemoresistant DTC detection and predictor of worse survival.

Fully equipped with the myriad of acquired alterations in cancer to go forth and multiply uncontrollably, this population of highly aggressive cells have the ability to sleep 'on the job'. While they slumber, they go undetected by powerful anti-cancer medicines since they currently only hone in on proliferating tumor cells. This enables DTC to travel to - and settle in - other organs and tissues in the body incognito, until they eventually wake up.

"In the current era of transformative medicine against cancer, we are increasingly delivering on the true promise of precision medicine in oncology. Two major challenges that hamper our collective efforts aimed at improving outcomes for our patients, are resistance to therapy and disease relapse. Concerning the latter, we need to move faster and get smarter in targeting and blasting these dormant cells as the seeders of tumors and metastatic cell spread," observes Héctor G. Palmer, corresponding author of this study.

Since dormant cancer cells are also notoriously difficult to detect among the army of normal cells in the body, the key to the team's research was finely-tuning their method of detecting and isolating them. He continues, "This was an essential element in the mix that enabled us to analyze these cells as known drivers of disease regression in patients thought to have been cured, as well as discover more about their molecular makeup."

The study showed that TET2 epigenetic enzyme activity, previously described as a tumor suppressor and downregulated in many tumor types, is increased in a small, stem-like cancer population and that elevated TET action is associated with chemoresitance. With the capacity to send these cancer cells to sleep, without sacrificing their potential malignant status, TET2 is a major orchestrator of their latent state.

"From the moment we identified TET2 as the Achilles heel of dormant tumor cells we have been focusing our efforts on developing novel inhibitors to block this enzyme activity. This new anti-cancer armory promises to counteract resistance and prevent relapse in some of our patients," observes Isabel Puig, first author of the paper.

Importantly, the researchers also identified a biomarker for the identification of this tricky-to-track and treatment-resistant population of cancer cells. Higher TET activity correlates with elevated levels of 5hmC as well as a greater risk of resistance to therapies and cancer recurrence.

"By detecting cells with 5hmC we can more precisely predict which patients are most likely to develop resistance to anti-cancer medicines as well as identify those who may suffer from relapse earlier on. Having seen that DTC are present across several tumor types including colon, breast and lung cancers as well as glioblastoma and melanoma, our findings could offer fresh hope for an important number of patients with advanced disease," she concludes.

Having driven precious insights into the molecular intricacies of these cells and expanded understanding surrounding their distinctive behavior, the team will seek to translate these two important findings into the clinic toward potentiating cancer therapeutics, preventing cancer relapse and extending survival of patients.
-end-
Incorporating leading scientists from several other VHIO groups, in collaboration with colleagues from other research centers of excellence across Spain and Switzerland, this multidisciplinary decade-long study was in part supported by the Spanish Association against Cancer (AECC), FERO Foundation, Instituto de Salud Carlos III (ISCIII), CIBERONC Network, and the CELLEX Foundation.

Vall d'Hebron Institute of Oncology

Related Cancer Articles:

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.
Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.
Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Warped Reality
False information on the internet makes it harder and harder to know what's true, and the consequences have been devastating. This hour, TED speakers explore ideas around technology and deception. Guests include law professor Danielle Citron, journalist Andrew Marantz, and computer scientist Joy Buolamwini.
Now Playing: Science for the People

#576 Science Communication in Creative Places
When you think of science communication, you might think of TED talks or museum talks or video talks, or... people giving lectures. It's a lot of people talking. But there's more to sci comm than that. This week host Bethany Brookshire talks to three people who have looked at science communication in places you might not expect it. We'll speak with Mauna Dasari, a graduate student at Notre Dame, about making mammals into a March Madness match. We'll talk with Sarah Garner, director of the Pathologists Assistant Program at Tulane University School of Medicine, who takes pathology instruction out of...
Now Playing: Radiolab

How to Win Friends and Influence Baboons
Baboon troops. We all know they're hierarchical. There's the big brutish alpha male who rules with a hairy iron fist, and then there's everybody else. Which is what Meg Crofoot thought too, before she used GPS collars to track the movements of a troop of baboons for a whole month. What she and her team learned from this data gave them a whole new understanding of baboon troop dynamics, and, moment to moment, who really has the power.  This episode was reported and produced by Annie McEwen. Support Radiolab by becoming a member today at Radiolab.org/donate.